Literature DB >> 10387470

The current and future therapy of allergic conjunctivitis.

M H Friedlaender1.   

Abstract

A wealth of antiallergic drugs is available for ocular allergy, and many new drugs will soon be approved. Pharmaceutical companies frequently seek approval of anti-inflammatory drugs for allergic indications, because it is relatively easy to perform clinical trials for ocular allergy. Extremely safe drugs for mild to moderate degrees of allergic conjunctivitis include antihistamines, mast cell stabilizers, and nonsteroidal anti-inflammatory agents. Topical corticosteroids, preferably those with reduced side effects, are available for more severe forms of ocular allergy. The choice of an antiallergic drug may be guided by the indication for which the drug was approved. The ultimate selection will be made based on the patient's symptoms, the drug's availability, and its cost.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10387470     DOI: 10.1097/00055735-199808000-00010

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  5 in total

Review 1.  Glucocorticoid receptor signaling in the eye.

Authors:  Rania S Sulaiman; Mahita Kadmiel; John A Cidlowski
Journal:  Steroids       Date:  2017-11-10       Impact factor: 2.668

Review 2.  [Ocular allergies].

Authors:  E M Messmer
Journal:  Ophthalmologe       Date:  2005-05       Impact factor: 1.059

3.  Corneal sensitivity after topical bromfenac sodium eye-drop instillation.

Authors:  Kaori Yanai; Jane Huang; Kazuaki Kadonosono; Eiichi Uchio
Journal:  Clin Ophthalmol       Date:  2013-04-17

Review 4.  The clinical spectrum of ocular allergy.

Authors:  Dominique Brémond-Gignac
Journal:  Curr Allergy Asthma Rep       Date:  2002-07       Impact factor: 4.919

5.  The effect of ketotifen on inflammatory markers in allergic conjunctivitis: an open, uncontrolled study.

Authors:  Andrea P Martín; Julio Urrets-Zavalia; Alejandro Berra; Ana Lía Mariani; Norberto Gallino; Eduardo Gomez Demel; Julio Gagliardi; Carlos E Baena-Cagnani; Enrique Urrets-Zavalia; Horacio M Serra
Journal:  BMC Ophthalmol       Date:  2003-01-06       Impact factor: 2.209

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.